4D Molecular Therapeutics Beheer
Beheer criteriumcontroles 2/4
4D Molecular Therapeutics' CEO is David Kirn, appointed in Sep 2013, has a tenure of 11.17 years. total yearly compensation is $10.29M, comprised of 5.8% salary and 94.2% bonuses, including company stock and options. directly owns 3.19% of the company’s shares, worth $13.43M. The average tenure of the management team and the board of directors is 3.1 years and 4 years respectively.
Belangrijke informatie
David Kirn
Algemeen directeur
US$10.3m
Totale compensatie
| Percentage CEO-salaris | 5.8% |
| Dienstverband CEO | 11.2yrs |
| Eigendom CEO | 3.2% |
| Management gemiddelde ambtstermijn | 3.1yrs |
| Gemiddelde ambtstermijn bestuur | 4yrs |
Recente managementupdates
Recent updates
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
Oct 044D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 10
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 194D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$110m |
| Mar 31 2024 | n/a | n/a | -US$105m |
| Dec 31 2023 | US$10m | US$597k | -US$101m |
| Sep 30 2023 | n/a | n/a | -US$96m |
| Jun 30 2023 | n/a | n/a | -US$111m |
| Mar 31 2023 | n/a | n/a | -US$110m |
| Dec 31 2022 | US$3m | US$586k | -US$107m |
| Sep 30 2022 | n/a | n/a | -US$105m |
| Jun 30 2022 | n/a | n/a | -US$102m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$5m | US$570k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$67m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$702k | US$451k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$61m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$554k | US$430k | -US$49m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$15m |
| Dec 31 2018 | US$546k | US$396k | -US$10m |
Compensatie versus markt: David's total compensation ($USD10.29M) is above average for companies of similar size in the US market ($USD2.42M).
Compensatie versus inkomsten: David's compensation has increased whilst the company is unprofitable.
CEO
David Kirn (61 yo)
11.2yrs
Tenure
US$10,286,808
Compensatie
Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013. Dr. Kirn...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 4.3yrs | US$581.44k | 0.19% $ 809.5k | |
| Co-Founder | 11.2yrs | US$10.29m | 3.19% $ 13.4m | |
| President & COO | 4.8yrs | US$4.54m | 0.011% $ 48.1k | |
| Chief Scientific Officer | less than a year | US$488.91k | geen gegevens | |
| Chief Medical Officer | 2.1yrs | US$3.96m | 0.0020% $ 8.5k | |
| Co-Founder & Chief of Staff | 11.8yrs | US$2.70m | geen gegevens | |
| Chief Financial & Business Officer | 1.2yrs | geen gegevens | geen gegevens | |
| Chief Legal Officer & Corporate Secretary | 3.2yrs | geen gegevens | 0.013% $ 54.9k | |
| Chief Development Officer | 3yrs | geen gegevens | geen gegevens | |
| Senior VP & Therapeutic Area Head of Pulmonology | no data | geen gegevens | geen gegevens | |
| Chief Commercial Officer | less than a year | geen gegevens | geen gegevens | |
| Controller | 8.3yrs | geen gegevens | geen gegevens |
3.1yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren management: FDMT's management team is considered experienced (3.1 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 4.3yrs | US$581.44k | 0.19% $ 809.5k | |
| Co-Founder | 11.2yrs | US$10.29m | 3.19% $ 13.4m | |
| Independent Director | 8.9yrs | US$352.62k | 0.062% $ 261.9k | |
| Independent Director | 4.3yrs | US$352.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | less than a year | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 5.7yrs | US$352.62k | 0% $ 0 | |
| Independent Director | 4yrs | US$345.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | less than a year | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 4yrs | US$340.12k | 0% $ 0 | |
| Chair of Ophthalmology Advisory Board | less than a year | geen gegevens | geen gegevens |
4.0yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: FDMT's board of directors are considered experienced (4 years average tenure).